Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor biologic therapy: a randomized, controlled trial

Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), was evaluated in a phase II randomized, double-blind, placebo-controlled study to investigate the efficacy and safety in patients with rheumatoid a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy 2019-04, Vol.21 (1)
Hauptverfasser:	Taylor, Peter C, Saurigny, Didier, Vencovsky, Jiri, Takeuchi, Tsutomu, Nakamura, Tadashi, Matsievskaia, Galina, Hunt, Barbara, Wagner, Thomas, Souberbielle, Bernard
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Arthritis Bronchitis C-reactive protein Clinical trials Common cold Drug therapy Headache Health aspects Heart attack Immunoglobulins Macrophage colony stimulating factor Macrophages Medical research Methotrexate Monoclonal antibodies Necrosis Patient outcomes Rheumatoid arthritis Rheumatoid factor Testing Tumor necrosis factor Tumor necrosis factor inhibitors Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!